Skip to main content

Von Willebrand Diseases clinical trials at UCSF

1 research study open to eligible people

Showing trials for
  • Minimize Menorrhagia in Women With Von Willebrand Disease

    open to eligible females ages 13-45

    This is an outpatient, 24-week Phase III prospective, randomized, crossover trial comparing recombinant von Willebrand factor (rVWF) and tranexamic acid (TA, Lysteda®) to minimize menorrhagia in women with von Willebrand disease (VWD). The purpose of this Phase III multicenter prospective, randomized, crossover arm trial is to compare recombinant von Willebrand factor (rVWF) to tranexamic acid (TA) in reducing the severity of menorrhagia in women with von Willebrand disease.

    San Francisco, California and other locations

Last updated: